This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.
This trial was terminated before completion. Termination can indicate safety signals, futility findings, or business/regulatory decisions by the sponsor.
Gossamer Bio (GOSS) is the sponsoring company for this trial. BiotechSign currently grades this company F (21/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.